Eli Lilly (LLY) Stock Overview
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
LLY Community Fair Values
Create NarrativeSee what 695 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Eli Lilly and Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$989.12 |
| 52 Week High | US$1,133.95 |
| 52 Week Low | US$623.78 |
| Beta | 0.43 |
| 1 Month Change | -4.89% |
| 3 Month Change | -6.18% |
| 1 Year Change | 19.93% |
| 3 Year Change | 196.50% |
| 5 Year Change | 432.24% |
| Change since IPO | 35,117.62% |
Recent News & Updates
Recent updates
Eli Lilly and Company (NYSE:LLY) Just Released Its Yearly Earnings: Here's What Analysts Think
Feb 07
Investors Appear Satisfied With Eli Lilly and Company's (NYSE:LLY) Prospects As Shares Rocket 30%
Nov 25Eli Lilly (NYSE:LLY) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Nov 07
Eli Lilly's Future Growth Driven by Tirzepatide and Favorable Market Conditions
Catalysts Mounjaro/Zepbound: Lilly’s tirzepatide franchise is the engine of growth. Mounjaro (for type 2 diabetes) and Zepbound (obesity) each grew rapidly in 2024.Shareholder Returns
| LLY | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -1.9% | -1.9% | -2.4% |
| 1Y | 19.9% | 23.8% | 16.8% |
Return vs Industry: LLY underperformed the US Pharmaceuticals industry which returned 23.8% over the past year.
Return vs Market: LLY exceeded the US Market which returned 16.8% over the past year.
Price Volatility
| LLY volatility | |
|---|---|
| LLY Average Weekly Movement | 5.6% |
| Pharmaceuticals Industry Average Movement | 9.2% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in US Market | 15.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: LLY has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: LLY's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1876 | 50,000 | Dave Ricks | www.lilly.com |
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin’s lymphoma; and Verzenio for breast cancer.
Eli Lilly and Company Fundamentals Summary
| LLY fundamental statistics | |
|---|---|
| Market cap | US$880.03b |
| Earnings (TTM) | US$20.64b |
| Revenue (TTM) | US$65.18b |
Is LLY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LLY income statement (TTM) | |
|---|---|
| Revenue | US$65.18b |
| Cost of Revenue | US$11.05b |
| Gross Profit | US$54.13b |
| Other Expenses | US$33.49b |
| Earnings | US$20.64b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Apr 30, 2026
| Earnings per share (EPS) | 23.10 |
| Gross Margin | 83.04% |
| Net Profit Margin | 31.67% |
| Debt/Equity Ratio | 160.2% |
How did LLY perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/16 08:22 |
| End of Day Share Price | 2026/03/16 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Eli Lilly and Company is covered by 53 analysts. 27 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Emily Field | Barclays |
| Kerry Holford | Berenberg |